|
Updated VFC/WyVIP formulary: Vaxneuvance and Priorix
Immunization Unit Staff
Vaxneuvance Pneumococcal 15-valent conjugate Merck vaccine and Priorix MMR GSK vaccine will be available to order for Vaccines for Children (VFC) enrolled providers beginning December 1, 2022.
Vaxneuvance (PCV15) can be used interchangeably with Pfizer’s Prevnar13 vaccine (PCV13). Priorix can be used interchangeably with Merck’s M-M-RII vaccine.
If your clinic chooses to switch to one of the newly available vaccine products, we ask that you use your remaining Prevnar13 and/or M-M-RII inventory before switching to a different brand, to minimize vaccine wastage. The Prevnar13 and M-M-RII vaccine presentations will remain on the VFC formulary for ordering.
The following clinical guidance is provided for the VFC use of Vaxneuvance and Priorix vaccines.
Vaxneuvance (PCV15)
Indications and recommendations for use
PCV vaccine is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae. Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F are included in PCV13; PCV15 contains serotypes 22F and 33F in addition to the PCV13 serotypes. On June 22, 2022, the Advisory Committee on Immunization Practices (ACIP) recommended use of PCV15 as an option for pneumococcal conjugate vaccination of persons aged <19 years, according to currently recommended PCV13 dosing and schedules. Risk-based recommendations on the use of PPSV23 have not changed.
PCV13 and PCV15:
- can be used interchangeably.
- are recommended for all children aged 2-59 months and some others based on risk factors.
- can be administered at the same time as other routine vaccines, including COVID-19, using separate syringes and different injection sites.
ACIP recommends the use of either PCV13 or PCV15 for all children aged 2-59 months. In addition, risk-based PCV use (either PCV13 or PCV15) is recommended for children aged 60-71 months with risk conditions, and persons aged 6-18 years with an immunocompromising condition, cerebrospinal fluid leak, or cochlear implant. For all recommendations, PCV13 and PCV15 can be used interchangeably. Interruption of the vaccination schedule does not require restarting the entire series or adding extra doses.
Vaccine administration
PCV13 and PCV15 are both available in a single-dose prefilled syringe as a 0.5 mL dose administered intramuscularly. Either PCV13 or PCV15 can be administered at the same time as other routine childhood vaccinations, including COVID-19 vaccines, in separate syringes and using different injection sites. The most common side effects of PCV15 are similar to those seen with PCV13: for children less than 2 years of age - irritability, excess sleepiness, injection site pain, fever, decreased appetite, injection site induration, redness, and/or swelling. Side effects typically go away within three days.
Recommended schedule and intervals
Infants and young children should receive PCV13 or PCV15 as a 4-dose series at 2, 4, 6, and 12-15 months of age (see table 1).
Older children through age 59 months may be vaccinated with PCV13 or PCV15 if they did not receive the recommended doses (see table 2).
Children and adolescents 6-18 years of age with certain medical conditions should receive a single dose of PCV13 or PCV15 if they did not already receive PCV13 or PCV15 (see table 3).
Precautions and contraindications
Vaxneuvance is contraindicated for individuals with a severe allergic reaction (e.g., anaphylaxis) to any component of Vaxneuvance or to diphtheria toxoid. The same precautions used for coadministration of PCV13 and meningococcal vaccines should be applied when PCV15 is used (i.e., for high risk individuals requiring both MCV and PCV vaccinations - MCV4 and PCV must be separated by at least 4 weeks, MCV4O can be given at the same time as PCV). Risk for febrile seizures in children who received PCV15 concurrently with an influenza vaccine has not been studied. Young children may be at increased risk for seizures caused by fever after PCV13 if administered at the same time as inactivated influenza vaccine. Apnea following intramuscular vaccination has been observed in some infants born prematurely. A decision about when to administer Vaxneuvance to infants born prematurely should be based on consideration of the individual infant’s medical status and the potential benefits and possible risks of vaccination.
PCV15 Resources:
Priorix
Indications and recommendations for use
Priorix is indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age and older. The FDA approved Priorix vaccine on June 3, 2022. No advisory committee meeting was held since a similar vaccine from a different manufacturer has been on the market for many years. In addition, given the similarities in dosage and vaccine components, the evidence from the clinical trials and literature review, the ACIP Work Group considers Priorix and M-M-R-II fully interchangeable, including all off-label uses.
Priorix and M-M-RII:
Can be used interchangeably.
Are recommended for all children aged 12 months of age and older.
Can be administered at the same time as other routine vaccines, including COVID-19, using separate syringes and different injection sites.
Priorix (GSK) and M-M-RII (Merck) can be used interchangeably according to the currently recommended MMR dosing and schedules. Like M-M-R-II, Priorix is supplied in lyophilized form and requires reconstitution. Priorix is stored at refrigerated temperatures between 2°C and 8°C (between 36°F and 46°F), and should not be stored in the freezer. Reconstituted vaccine should be used immediately, or stored refrigerated and administered within 8 hours.
Vaccine administration
Priorix is supplied as a single-dose vial of lyophilized antigen component to be reconstituted with the accompanying prefilled syringe of sterile water diluent component. A single dose after reconstitution is approximately 0.5 mL, and should be administered subcutaneously. The first dose is administered at 12 through 15 months of age, and the second dose is administered at 4 through 6 years of age. If either MMR vaccine is not administered according to the routine schedule, there should be a minimum of 4 weeks between the first and second dose. The most common side effects seen with Priorix are similar to those seen with M-M-R-II; pain, redness, swelling at the injection site, irritability, loss of appetite, drowsiness, and fever. Swelling of the parotid glands or temporary pain and stiffness in the joints sometimes occur after MMR vaccination.
Recommended schedule and intervals
Children need 2 doses of MMR vaccine; the first dose at age 12 through 15 months, and the second dose at age 4 through 6 years.
Infants who will be traveling outside of the United States when they are between 6 and 11 months of age should get a dose of MMR vaccine before travel.
Older children, adolescents, and adults need 1 or 2 doses of MMR vaccine if they are not already immune to measles, mumps, and rubella.
If MMR vaccine is not administered according to the routine schedule, there should be a minimum of 4 weeks between the first and second dose.
Precautions and contraindications
Contraindications to Priorix include a history of a severe allergic reaction (e.g., anaphylaxis) to any component of Priorix, or after a previous dose of any measles, mumps, and rubella virus-containing vaccine, severe immunodeficiency, and pregnancy. More serious, and rare reactions include seizures or temporary low platelet count. The tip caps of the prefilled syringes of Priorix vaccine contain natural rubber latex, which may cause allergic reactions. Administration of immune globulins and other blood products concurrently with Priorix may interfere with the expected immune response to the vaccine. Priorix may result in a temporary suppression of tuberculin reactivity.
Priorix resources:
|